Dendritic Cell Vaccines Volume II
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 6660
Special Issue Editors
Interests: immunopharmacology; pharmacotoxicology; innate immune cells; inflammation; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Interests: immunobiology of innate immune cells; signal transduction; cell-based therapies
Special Issues, Collections and Topics in MDPI journals
Interests: tumor immunotherapy; dendritic cells biology; cell-based vaccines
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
At the interface between the innate and adaptive immune system, dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is exploitable in DC vaccination strategies, in which DCs (endogenous or differentiated ex-vivo) are manipulated to prime or boost a tumor-specific immune response. DC vaccination remains a promising approach with the potential to further improve cancer immunotherapy with little or no evidence of treatment-limiting toxicity. However, evidence for objective clinical antitumor activity of DC vaccination is currently limited, hampering the clinical implementation. Indeed, DC-based vaccines long-term efficacy depends on a number of parameters that are often underestimated, encompassing the immunosuppressive circuitries that are in place in the microenvironment of most solid tumors, the evolution of antigen-loss variants, the need for the establishment of clinical standard operating procedures and the overall immunological competence of the patient. Therefore, to improve their clinical efficacy, it is mandatory to design novel and improved strategies that can boost adaptive and innate immunity against cancer, helping to overcome DCs-vaccines limitations.
This Special Issue of Pharmaceutics focuses on new approaches to improve the immunogenic profile of DCs towards tumor cells, paving the way to the development of new DCs-based immunotherapeutic strategies. We welcome articles concerning all aspects covering the key biological qualities of DCs for immunotherapy, the wide range of adjuvants available, the multiple forms of tumor antigen loading, and different schedules and routes of vaccine administration. The potential to strengthen responses with other anti-cancer combinatorial approaches to boost the clinical potency of DC-based vaccines is also welcome.
We invite experts from academia or industry to contribute to this Special Issue with original research articles or reviews.
Dr. Maria Teresa Cruz
Prof. Dr. Bruno Miguel Neves
Dr. Mylène Carrascal
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dendritic cells
- cancer vaccines
- immunotherapy
- cell-based therapy
- tumor antigens
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Related Special Issue
- Dendritic Cell Vaccines in Pharmaceutics (9 articles)
